# Quick Reference Guide HEDIS<sup>®</sup> MY 2022



For more information, visit www.ncqa.org

HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance, or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile, or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal noncommercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use, or any external reproduction, distribution, or publication must be approved by NCQA and are subject to a license at the discretion of NCQA.



## HEDIS<sup>®</sup> MY 2022 Quick Reference Guide

#### Updated to reflect NCQA HEDIS® MY 2022 Technical Specifications

WellCare strives to provide quality healthcare to our membership as measured through HEDIS<sup>®</sup> quality metrics. We created the HEDIS<sup>®</sup> MY 2022 Quick Reference Guide to help you increase your practice's HEDIS<sup>®</sup> rates and to use to address care opportunities for your patients. Please always follow the state and/or CMS billing guidance and ensure the HEDIS<sup>®</sup> codes are covered prior to submission.



#### What is HEDIS<sup>®</sup>?

HEDIS<sup>®</sup> (Healthcare Effectiveness Data and Information Set) is a set of standardized performance measures developed by the National Committee for Quality Assurance (NCQA) to objectively measure, report, and compare quality across health plans. NCQA develops HEDIS<sup>®</sup> measures through a committee represented by purchasers, consumers, health plans, health care providers, and policy makers.



#### What are the scores used for?

As state and federal governments move toward a quality-driven healthcare industry, HEDIS<sup>®</sup> rates are becoming more important for both health plans and individual providers. State purchasers of healthcare use aggregated HEDIS<sup>®</sup> rates to evaluate health insurance companies' efforts to improve preventive health outreach for members.

Physician-specific scores are also used to measure your practice's preventive care efforts. Your practice's HEDIS<sup>®</sup> score determines your rates for physician incentive programs that pay you an increased premium — for example Pay For Performance or Quality Bonus Funds.



#### How are rates calculated?

HEDIS<sup>®</sup> rates can be calculated in two ways: administrative data or hybrid data. Administrative data consists of claim or encounter data submitted to the health plan. Hybrid data consists of both administrative data and a sample of medical record data. Hybrid data requires review of a random sample of member medical records to abstract data for services rendered but that were not reported to the health plan through claims/encounter data. Accurate and timely claim/encounter data reduces the need for medical record review. If services are not billed or not billed accurately, they are not included in the calculation.



#### How can I improve my HEDIS<sup>®</sup> scores?

- Submit claim/encounter data for each and every service rendered
- Make sure that chart documentation reflects all services billed
- Bill (or report by encounter submission) for all delivered services, regardless of contract status
- Ensure that all claim/encounter data is submitted in an accurate and timely manner
- Consider including CPT II codes to provide additional details and reduce medical record requests

This guide has been updated with information from the release of the HEDIS<sup>®</sup> MY 2022 Volume 2 Technical Specifications by NCQA and is subject to change.



## Contents

5
21

# Adult Health



### (AAP) Adults' Access to Preventive/ Ambulatory Health Services

Measure evaluates the percentage of members 20 years and older who had an ambulatory or preventive care visit. Services that count include outpatient evaluation and management (E&M) visits, consultations, assisted living/home care oversight, preventive medicine, and counseling.

CPT*	HCPCS*	ICD-10*
99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 92002, 92004, 92012, 92014, 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337, 98966-98968, 99441-99443, 98969, 98970, 98971, 98972, 99421, 99422, 99423, 99444, 99457, 99483	G0071, G0402, G0438, G0439, G0463, G2010, G2012, G2061, G2062, G2063, T1015, S0620, S0621	Z00.00, Z00.01, Z00.3, Z00.5, Z00.8, Z00.121, Z00.129, Z02.0, Z02.1, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9, Z76.1, Z76.2



Measure evaluates percentage of adults:

✓ 66-80 years of age with advanced illness, an indication of frailty, or who are receiving palliative care and had advance care planning;



✓ 81 years of age and older who had advance care planning

Description	Codes*
Advanced Care Planning	<b>CPT:</b> 99483, 99497
	CPT-CAT-II: 1123F, 1124F, 1157F, 1158F
	HCPCS: S0257
	ICD-10: Z66

\*Codes subject to change



#### (AMM) Antidepressant **Medication Management**

Measure evaluates percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment.

#### Two rates are reported:



Effective Acute Phase Treatment: percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks)



2 Effective Continuation Phase Treatment: percentage of members who remained on an antidepressant medication for at least 180 days (6 months)

#### (AMM) Antidepressant Medication Management (continued)

Antidepressant Medications			
Description	Prescription		
Miscellaneous antidepressants	<ul><li>Bupropion</li><li>Vortioxetine</li></ul>	• Vilazodone	
Monoamine oxidase inhibitors	<ul><li>Isocarboxazid</li><li>Phenelzine</li></ul>	<ul><li>Selegiline</li><li>Tranylcypromine</li></ul>	
Phenylpiperazine antidepressants	• Nefazodone	• Trazodone	
Psychotherapeutic combinations	<ul> <li>Amitriptyline-chlordiazepoxide</li> <li>Fluoxetine-olanzapine</li> <li>Amitriptyline-perphenazine</li> </ul>		
SNRI antidepressants	<ul><li>Desvenlafaxine</li><li>Duloxetine</li><li>Venlafaxine</li><li>Levomilnacipran</li></ul>		
SSRI antidepressants	<ul><li>Citalopram</li><li>Fluvoxamine</li></ul>	<ul><li>Escitalopram</li><li>Paroxetine</li></ul>	<ul><li>Fluoxetine</li><li>Sertraline</li></ul>
Tetracyclic antidepressants	• Maprotiline	• Mirtazapine	
Tricyclic antidepressants	<ul><li> Amitriptyline</li><li> Desipramine</li><li> Nortriptyline</li></ul>	<ul><li> Amoxapine</li><li> Doxepin (&gt;6 mg)</li><li> Protriptyline</li></ul>	<ul><li>Clomipramine</li><li>Imipramine</li><li>Trimipramine</li></ul>

#### (BPD) Blood Pressure Control for Patients With Diabetes

Measure evaluates percentage of members 18-75 years of age with diabetes (type 1 and type 2) whose blood pressure was adequately controlled (<140/90 mm Hg).

Description	Codes*
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5
Outpatient Codes (must include a diagnosis of diabetes)	<b>CPT:</b> 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99987, 99391-99397, 99401, 99402, 99403, 99404, 99411, 99412, 99429, 99455, 99456, 99483 <b>HCPCS:</b> G0402, G0438, G0439, G0463, T1015
Non-Acute Inpatient (must include a diagnosis of diabetes)	<b>CPT:</b> 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
Telephone Visits (must include a diagnosis of diabetes)	<b>CPT:</b> 98966-98968, 99441-99443
E-Visits or Virtual Check-ins (must include a diagnosis of diabetes)	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061-G2063
Systolic Greater Than/ Equal to 140	<b>CPT-CAT-II:</b> 3077F
Systolic Less Than 140	<b>CPT-CAT-II:</b> 3074F, 3075F
Diastolic 80-89	<b>CPT-CAT-II:</b> 3079F
Diastolic Greater Than/ Equal to 90	<b>CPT-CAT-II:</b> 3080F
Diastolic Less Than 80	<b>CPT-CAT-II:</b> 3078F

## (CBP) Controlling High Blood Pressure

Measure evaluates the percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg).

Description	Codes*
Essential Hypertension	ICD-10: 110
Systolic Greater Than/Equal to 140	<b>CPT-CAT-II:</b> 3077F
Systolic Less Than 140	CPT-CAT-II: 3074F, 3075F
Diastolic Greater Than/Equal to 90	<b>CPT-CAT-II:</b> 3080F
Diastolic 80-89	<b>CPT-CAT-II:</b> 3079F
Diastolic Less Than 80	<b>CPT-CAT-II:</b> 3078F
Telephone Visits	<b>CPT:</b> 98966-98968, 99441-99443
Palliative Care	HCPCS: G9054, M1017
	ICD-10: Z51.5

\*Codes subject to change

## (COA) Care for Older Adults

Measure evaluates percentage of adults 66 years and older who had each of the following:

Medication review

- ✓ Functional status assessment
- ✓ Pain assessment
- Description Codes\* **Medication Review CPT:** 90863, 99605, 99606, 99483, (would need both CPT-CAT II 99495.99496 codes to get credit) CPT-CAT-II: 1159F, 1160F 1159F (Medication List) & 1160F (Medication Review) **Functional Status Assessment CPT:** 99483 **CPT-CAT-II: 1170F** HCPCS: G0438. G0439 Pain Assessment **CPT-CAT-II:** 1125F, 1126F

## (COL) Colorectal Cancer Screening

Measure evaluates the percentage of members 45-75 years of age who has had an appropriate screening for colorectal cancer.

Description	Codes*
Colonoscopy	<b>CPT:</b> 44388-44394, 44397, 44401-44408, 45355, 45378-45393, 45398 <b>HCPCS:</b> G0105, G0121
CT Colonography	<b>CPT:</b> 74261-74263
sDNA FIT Lab Test	<b>CPT:</b> 81528
Flexible Sigmoidoscopy	<b>CPT:</b> 45330-45335, 45337-45338, 45340-45342 , 45346-45347, 45349-45350 <b>HCPCS:</b> G0104
FOBT Lab Test	<b>CPT:</b> 82270, 82274 <b>HCPCS:</b> G0328
Colorectal Cancer	<b>ICD-10:</b> C18.0-C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5
Total Colectomy	<b>CPT:</b> 44150-44153, 44155-44158, 44210-44212

### (EED) Eye Exam for Patients With Diabetes

Measure evaluates percentage of members 18-75 years of age with diabetes (type 1 and type 2) who had a retinal eye exam.

Description	Codes*
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5
Outpatient Codes (must include a diagnosis of diabetes)	<b>CPT:</b> 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401, 99402, 99403, 99404, 99411, 99412, 99429, 99455, 99456, 99483 <b>HCPCS:</b> G0402, G0438, G0439, G0463, T1015
Non-Acute Inpatient (must include a diagnosis of diabetes)	<b>CPT:</b> 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
Telephone Visits (must include a diagnosis of diabetes)	<b>CPT:</b> 98966-98968, 99441-99443
E-Visits or Virtual Check-ins (must include a diagnosis of diabetes)	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061-G2063
Unilateral Eye Enucleation With a Bilateral Modifier	<b>CPT:</b> 65091, 65093, 65101, 65103, 65105, 65110,65112, 65114 <b>CPT Modifier:</b> 50
Automated Eye Exam	<b>CPT:</b> 92229
Diabetic Retinal Screening Negative in Prior Year	<b>CPT-CAT-II:</b> 3072F
Eye Exam With Retinopathy	<b>CPT-CAT-II:</b> 2022F, 2024F, 2026F
Eye Exam Without Retinopathy	<b>CPT-CAT-II:</b> 2023F, 2025F, 2033F

### (HBD) Hemoglobin A1c Control for Patients With Diabetes

Measure evaluates percentage of members 18-75 years of age with diabetes (type 1 and type 2) whose HbA1c was at the following levels:

✓ HbA1c control (<8.0%) ✓ HbA1c Poor control (>9.0%)

Description	Codes*
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5
Outpatient Codes (must include a diagnosis of diabetes)	<b>CPT:</b> 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401, 99402, 99403, 99404, 99411, 99412, 99429, 99455, 99456, 99483 <b>HCPCS:</b> G0402, G0438, G0439, G0463, T1015
Non-Acute Inpatient (must include a diagnosis of diabetes)	<b>CPT:</b> 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
Telephone Visits (must include a diagnosis of diabetes)	<b>CPT:</b> 98966-98968, 99441-99443
E-Visits or Virtual Check-ins (must include a diagnosis of diabetes)	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061-G2063
HbA1c Lab Test	<b>CPT:</b> 83036, 83037
HbA1c Level Less than 7 Codes	<b>CPT-CAT-II:</b> 3044F
HbA1c Level Greater Than/Equal to 7 and Less than 8	<b>CPT-CAT-II:</b> 3051F
HbA1c Level Greater Than/Equal to 8 and Less Than/Equal to 9	<b>CPT-CAT-II:</b> 3052F
HbA1c Greater Than 9.0	<b>CPT-CAT-II:</b> 3046F

### (KED) Kidney Health Evaluation for Patients With Diabetes

The percentage of members 18–85 years of age with diabetes (Type 1 and Type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) *and* a urine albumin-creatinine ratio (uACR), during the measurement year.

Description	Codes*
Estimated Glomerular Filtration Rate (eGFR) – must be within 4 days or less of the uACR	<b>CPT:</b> 80047, 80048, 80050, 80053, 80069, 82565
Urine Albumin-Creatinine Ratio (uACR) – must be within 4 days or less of the eGFR	<b>CPT:</b> 82043, 82570
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5

### (PBH) Persistence of Beta-Blocker Treatment After a Heart Attack

This measure demonstrates the percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

Beta-Blocker Medication				
Description	Prescription			
Noncardioselective beta-blockers	<ul><li>Carvedilol</li><li>Propranolol</li></ul>	• Labetalol • Timolol	• Nadolol • Sotalol	• Pindolol
Cardioselective beta-blockers	• Acebutolol • Atenolol	<ul><li>Betaxolol</li><li>Bisoprolol</li></ul>	<ul><li>Metoprol</li><li>Nebivolol</li></ul>	
Antihypertensive combinations	<ul> <li>Atenolol-chlorthalidone</li> <li>Bendroflumethiazide-nadolol</li> <li>Bisoprolol-hydrochlorothiazide</li> <li>Hydrochlorothiazide-metoprolol</li> <li>Hydrochlorothiazide-propranolol</li> </ul>			

### (PCE) Pharmacotherapy Management of COPD Exacerbation

Measure evaluates percentage of COPD exacerbations for members 40 years of age and older who had an acute inpatient discharge or ED visit on or between January 1-November 30 and were dispensed appropriate medications.

#### Two rates are reported:



Dispensed a systemic corticosteroid (or there was evidence) of an active prescription) within 14 days of the event



Dispensed a **bronchodilator** (or there was evidence of an active prescription) within 30 days of the event

#### (PCE) Pharmacotherapy Management of COPD Exacerbation (continued)

Systemic Corticosteroid Medications			
Description	Prescription		
Glucocorticoids	<ul><li>Cortisone</li><li>Prednisolone</li><li>Methylprednisolone</li></ul>	<ul><li>Hydrocortisone</li><li>Dexamethasone</li><li>Prednisone</li></ul>	
Bronchodilator I	Medications		
Description	Prescription		
Anticholinergic agents	<ul><li>Aclidinium-bromide</li><li>Ipratropium</li></ul>	• Umeclidinium • Tiotropium	
Beta 2-agonists	<ul><li>Albuterol</li><li>Metaproterenol</li><li>Indacaterol</li></ul>	<ul><li>Levalbuterol</li><li>Formoterol</li><li>Oledaterol</li><li>Arformoterol</li><li>Salmeterol</li></ul>	
Bronchodilator combinations	<ul> <li>Albuterol-ipratropium</li> <li>Budesonide-formoterol</li> <li>Formoterol-mometasone</li> <li>Glycopyrrolate-indacaterol</li> <li>Umeclidinium-Vilanterol</li> <li>Olodaterol-tiotropium</li> <li>Formoterol-aclidinium</li> <li>Fluticasone-salmeterol</li> <li>Fluticasone furgate- umeclidinium-vilarterol</li> </ul>		

#### (SMD) Diabetes Monitoring for People With Diabetes and Schizophrenia

Measure evaluates the percentage of members 18-64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1c test.

Description	Prescription
HbA1c Lab Tests	<b>CPT:</b> 83036, 83037 <b>CPT-CAT-II:</b> 3044F, 3046F, 3051F, 3052F
LDL-C Lab Tests	<b>CPT:</b> 80061, 83700, 83701, 83704, 83721 <b>CPT-CAT-II:</b> 3048F, 3049F, 3050F

# (SPR) Use of Spirometry Testing in the Assessment and Diagnosis of COPD

Measure evaluates the percentage of members 40 years of age and older with a new diagnosis of COPD or newly active COPD, who received appropriate spirometry testing to confirm diagnosis.

#### CPT\*

94010, 94014-94016, 94060, 94070, 94375, 94620

\*Codes subject to change

### (SSD) Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Measure evaluates percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test.

Description	Codes*
HbA1c Lab Tests	<b>CPT:</b> 83036, 83037 <b>CPT-CAT-II:</b> 3044F, 3046F, 3051F, 3052F
Glucose Lab Tests	<b>CPT:</b> 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951



# Women's Health



## (BCS) Breast Cancer Screening

Measure evaluates the percentage of women 50-74 years of age who had a mammogram to screen for breast cancer.

Description	Codes*
Mammogram	<b>CPT:</b> 77061-77063, 77065-77067 <b>ICD-10 (bilateral mastectomy):</b> Z90.13
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5

\*Codes subject to change



## (CCS) Cervical Cancer Screening

This measure demonstrates the percentage of women 21-64 years of age who were screened for cervical cancer using **either** of the following criteria:

- Women 21-64 years of age who had cervical cytology performed within last 3 years.
- Women 30-64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.

 Women 30-64 years of age who had cervical cytology/high risk human papillomavirus (hrHPV) co-testing within the last 5 years.



#### (CCS) Cervical Cancer Screening (continued)

Description	Codes*
Cervical Cytology Lab Test (20-64)	<b>CPT:</b> 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175 <b>HCPCS:</b> G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091
HPV Tests (30-64)	<b>CPT:</b> 87624, 87625 <b>HCPCS:</b> G0476
Hysterectomy with No Residual Cervix and Absence of Cervix Diagnosis	<b>CPT:</b> 51925, 56308, 57530, 57531, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550, 58552- 58554, 58570-58573, 58575, 58951, 58953, 58954, 58956, 59135 <b>ICD-10:</b> Q51.5, Z90.710, Z90.712
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5

\*Codes subject to change



## (CHL) Chlamydia Screening in Women

Measure evaluates the percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia.

#### CPT\*

87110, 87270, 87320, 87490-87492, 87810

#### (OMW) Osteoporosis Management in Women Who Had a Fracture

Measure evaluates the percentage of women 67-85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

Description	Codes*
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5
Bone Mineral Density Tests	<b>CPT:</b> 76977, 77078, 77080, 77081, 77085, 77086
Osteoporosis Medications	<b>HCPCS:</b> J0897, J1740, J3110, J3111, J3489
Long-Acting Osteoporosis Medications during Inpatient Stay	<b>HCPCS:</b> J0897, J1740, J3489

\*Codes subject to change

Osteoporosis Medications	
Description	Prescription
Bisphosphonates	<ul><li>Alendronate</li><li>Alendronate-cholecalciferol</li><li>Risedronate</li><li>Zoledronic acid</li></ul>
Other agents	<ul><li>Abaloparatide • Romosozumab • Denosumab</li><li>Teriparatide • Raloxifene</li></ul>

#### (OSW) Osteoporosis Screening in Older Women

The percentage of women 65–75 years of age who received osteoporosis screening.

Description	Codes*
Osteoporosis Screening Tests	<b>CPT:</b> 76977, 77078, 77080, 77081, 77085
Palliative Care	HCPCS: G9054, M1017 ICD-10: Z51.5



Measure evaluates percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care.

✓ Timeliness of Prenatal Care: percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date, or within 42 days of enrollment in the organization

 Postpartum Care: percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery

Description	Codes*
Online Assessments	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061, G2062, G2063
Prenatal Visits	<b>CPT:</b> 99201-99205, 99211-99215, 99241-99245, 99483 <b>HCPCS:</b> G0463, T1015
Stand-Alone Prenatal Visits	<b>CPT:</b> 99500 <b>CPT-CAT-II:</b> 0500F, 0501F, 0502F <b>HCPCS:</b> H1000, H1001, H1002, H1003, H1004
Cervical Cytology Lab Test	<b>CPT:</b> 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175 <b>HCPCS:</b> G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091
Postpartum Visits	<b>CPT:</b> 57170, 58300, 59430, 99501 <b>CPT-CAT-II:</b> 0503F <b>HCPCS:</b> G0101 <b>ICD-10:</b> Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2
Telephone Visits	<b>CPT:</b> 98966-98968, 99441-99443

\*Codes subject to change

NOTE: When using the Online Assessment, Telephone Visit, or Prenatal Visit codes, remember to also include a Pregnancy Diagnosis code.

# Pediatric Health



### (ADD) Follow-up Care for Children Prescribed ADHD Medication

Measure evaluates percentage of children newly prescribed attention deficit hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.

#### Two rates are reported:

- **Initiation Phase:** percentage of members 6-12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
- 2 Continuation and Maintenance (C&M) Phase: percentage of members 6-12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended

Description	Codes*
An Outpatient Visit	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255 <b>POS:</b> 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72



#### (ADD) Follow-up Care for Children Prescribed ADHD Medication (continued)

Description	Codes*	
BH Outpatient Visit	<b>CPT:</b> 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99510, 99483, 99492-99494 <b>HCPCS:</b> G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, T1015	
<b>Observation Visit</b>	<b>CPT:</b> 99217-99220	
Health and Behavior Assessment/ Intervention	<b>CPT:</b> 96150-96154, 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, 96171	
Visit Setting Unspecified Value Set with Partial Hospitalization POS	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255 <b>POS:</b> 52	
Partial Hospitalization/ Intensive Outpatient	<b>HCPCS:</b> G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485	
Telehealth Visit	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255 <b>POS:</b> 02, 10	
Telephone Visits	<b>CPT:</b> 98966-98968, 99441-99443	
E-visit/Virtual Check-In	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061, G2062, G2063	
Visit Setting Unspecified Value Set with Community Mental Health Center POS	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255 <b>POS:</b> 53	
Narcolepsy	ICD-10: G47.411, G47.419, G47.421, G47.429	

### (APM) Metabolic Monitoring for Children and Adolescents on Antipsychotics

This measure demonstrates the percentage of children and adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

#### Three rates reported:



Percentage of children and adolescents on antipsychotics who received blood glucose testing



Percentage of children and adolescents on antipsychotics who received cholesterol testing

Percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing

Description (Need either A1c or Glucose and LCL-C or Cholesterol)	Codes*
HbA1c Lab Tests	<b>CPT:</b> 83036, 83037 <b>CPT-CAT-II:</b> 3044F, 3046F, 3051F, 3052F
Glucose Lab Tests	<b>CPT:</b> 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
LDL-C Lab Tests	<b>CPT:</b> 80061, 83700, 83701, 83704, 83721 <b>CPT-CAT-II:</b> 3048F, 3049F, 3050F
Cholesterol Lab Tests	<b>CPT:</b> 82465, 83718, 83722, 84478

## field

#### (CIS) Childhood Immunization Status

This measure demonstrates the percentage of children 2 years of age who completed immunizations on or before child's second birthday.

Description	Codes*
DTaP (4 dose)	<b>CPT:</b> 90697, 90698, 90700, 90723 <b>CVX:</b> 20, 50, 106, 107, 110, 120, 146
HIB (3 dose)	<b>CPT:</b> 90644, 90647, 90648, 90697, 90698, 90748 <b>CVX:</b> 17, 46, 47, 48, 49, 50, 51, 120, 146, 148
Newborn Hep B (3 dose)	<b>CPT:</b> 90697, 90723, 90740, 90744, 90747, 90748 <b>CVX:</b> 08, 44, 45, 51, 110, 146 <b>HCPCS:</b> G0010 <b>ICD-10:</b> B16.0, B16.1, B16.2, B16.9, B17.0, B18.0, B18.1, B19.10, B19.11
IPV (3 dose)	<b>CPT:</b> 90697, 90698, 90713, 90723 <b>CVX:</b> 10, 89, 110, 120, 146
MMR (1 dose)	<b>CPT:</b> 90707, 90710 <b>CVX:</b> 03, 94 <b>ICD-10:</b> B05.0, B05.1, B05.2, B05.3, B05.4, B05.81, B05.89, B05.9, B26.0, B26.1, B26.2, B26.3, B26.81, B26.82. B26.83, B26.84, B26.85, B26.89, B26.9, B06.00, B06.01, B06.02, B06.09, B06.81, B06.82, B06.89, B06.9
Pneumococcal Conjugate PCV (4 dose)	<b>CPT:</b> 90670 <b>CVX:</b> 109, 133, 152 <b>HCPCS:</b> G0009
Varicella VZV (1 dose)	<b>CPT:</b> 90710, 90716 <b>CVX:</b> 21, 94 <b>ICD-10:</b> B01.0, B01.11, B01.12, B01.2, B01.81, B01.89, B01.9, B02.0, B02.1, B02.21, B02.22, B02.23, B02.24, B02.29, B02.30, B02.31, B02.32, B02.33, B02.34, B02.39, B02.7, B02.8, B02.9

#### (CIS) Childhood Immunization Status (continued)

Description	Codes*
Hep A (1 dose)	<b>CPT:</b> 90633 <b>CVX:</b> 31, 83, 85 <b>ICD-10:</b> B15.0, B15.9
<b>Influenza Flu (2 dose)</b> LAIV vaccination must be administered on the child's 2nd birthday	<b>CPT:</b> 90655, 90657, 90660, 90661, 90672, 90673, 90674, 90685-90689, 90756 <b>CVX:</b> 88, 140, 141, 150, 153, 155, 158, 161, 111, 149, 171, 186 <b>HCPCS:</b> G0008
Rotavirus (2 Dose)	<b>CPT:</b> 90681 <b>CVX:</b> 119
Rotavirus (3 Dose)	<b>CPT:</b> 90680 <b>CVX:</b> 116, 122
Anaphylaxis	Use applicable SNOMED as indicated per vaccine

\*Codes subject to change

NOTE: Rotavirus is either 2 dose **OR** 3 dose for compliancy



### (IMA) Immunizations for Adolescents

Measure evaluates percentage of adolescents 13 years of age who completed immunizations on or before member's 13th birthday

Description	Codes*
Meningococcal – serogroup A,C,W, and Y: (1 dose)	<b>CPT:</b> 90619, 90733, 90734 <b>CVX:</b> 32, 108, 114, 136, 147, 167, 203
Tdap (1 dose)	<b>CPT:</b> 90715 <b>CVX:</b> 115
HPV (2 or 3 dose series)	<b>CPT:</b> 90649-90651 <b>CVX:</b> 62, 118, 137, 165
Anaphylaxis	Use applicable SNOMED as indicated per vaccine

## (LSC) Lead Screening in Children

Measure evaluates percentage of children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.

CPT*			
83655			

\*Codes subject to change

### (W30/WCV) Well-Child and Adolescent Well-Care Visits

The percentage of members within designated ages who had comprehensive well-care visit(s) as defined in each measure, with a PCP or an OB/GYN practitioner during the measurement year.

(W30) Well-Child Visits in the First 30 Months of Life: Children who had the following number of well-child visits with PCP during the last 15 months.

#### The following rates are reported:



Well-Child Visits in the First 15 Months. Children who turned 15 months old during the measurement year: Six or more well-child visits.



Well-Child Visits for Age 15 Months–30 Months. Children who turned 30 months old during the measurement year: Two or more well-child visits.

CPT*	HCPCS*	ICD-10*
99381, 99382, 99391,	G0438, G0439,	Z00.110, Z00.111, Z00.121,
99392, 99461	S0302	Z00.129, Z00.2, Z76.1, Z76.2

\*Codes subject to change

#### (W30/WCV) Well-Child and Adolescent Well-Care Visits (continued)

#### (WCV) Child and Adolescent Well-Care Visits: Members 3-21 years

of age who had a least one comprehensive well-care visit with a PCP or an OB/GYN

CPT*	HCPCS*	ICD-10*
99382-99385, 99391-99395	G0438, G0439, S0302, S0610, S0612, S0613	Z00.00, Z00.01, Z00.121, Z00.129, Z00.2, Z00.3, Z01.411, Z01.419, Z02.5, Z76.2

\*Codes subject to change

#### (WCC) Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

This measure demonstrates the percentage of members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following:

- ✓ BMI Percentile
- Counseling for Nutrition
- Counseling for physical activity

Description	Codes*
BMI Percentile	ICD-10: Z68.51, Z68.52, Z68.53, Z68.54
Nutrition Counseling	<b>CPT:</b> 97802-97804 <b>HCPCS:</b> G0270, G0271, G0447, S9449, S9452, S9470 <b>ICD-10:</b> Z71.3
Physical Activity	<b>HCPCS:</b> G0447, S9451 <b>ICD-10:</b> Z02.5, Z71.82

# General Health



## (AMR) Asthma Medication Ratio

Measure evaluates the percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medication of 0.50 or greater.

- **Step 1:** For each member, count the units of asthma controller medications (Asthma Controller Medications List) dispensed during the measurement year.
- **Step 2:** For each member, count the units of asthma reliever medications (Asthma Reliever Medications List) dispensed during the measurement year.
  - For each member, sum the units calculated in step 1 and step 2 to determine units of total asthma medications
  - $\checkmark$  For each member, calculate ratio using the below:
    - Units of Controller Medications/Units of Total Asthma Medications

Asthma Controller Medications			
Description	Prescriptions	Medication Lists	Route
Antibody inhibitors	Omalizumab	Omalizumab Medications List	Injection
Anti-interleukin-4	Dupilumab	Dupilumab Medications List	Injection

#### (AMR) Asthma Medication Ratio (continued)

Asthma Controller Medications			
Description	Prescriptions	Medication Lists	Route
Anti-interleukin-5	Benralizumab	Benralizumab Medications List	Injection
Anti-interleukin-5	Mepolizumab	Mepolizumab Medications List	Injection
Anti-interleukin-5	Reslizumab	Reslizumab Medications List	Injection
Inhaled steroid combinations	Budesonide- formoterol	Budesonide Formoterol Medications List	Inhalation
Inhaled steroid combinations	Fluticasone- salmeterol	Fluticasone Salmeterol Medications List	Inhalation
Inhaled steroid combinations	Fluticasone- vilanterol	Fluticasone Vilanterol Medications List	Inhalation
Inhaled steroid combinations	Formoterol- mometasone	Formoterol Mometasone Medications List	Inhalation
Inhaled corticosteroids	Beclomethasone	Beclomethasone Medications List	Inhalation
Inhaled corticosteroids	Budesonide	Budesonide Medications List	Inhalation
Inhaled corticosteroids	Ciclesonide	Ciclesonide Medications List	Inhalation
Inhaled corticosteroids	Flunisolide	Flunisolide Medications List	Inhalation
Inhaled corticosteroids	Fluticasone	Fluticasone Medications List	Inhalation
Inhaled corticosteroids	Mometasone	Mometasone Medications List	Inhalation

#### (AMR) Asthma Medication Ratio (continued)

Asthma Controller Medications			
Description	Prescriptions	Medication Lists	Route
Leukotriene modifiers	Montelukast	Montelukast Medications List	Oral
Leukotriene modifiers	Zafirlukast	Zafirlukast Medications List	Oral
Leukotriene modifiers	Zileuton	Zileuton Medications List	Oral
Methylxanthines	Theophylline	Theophylline Medications List	Oral

Asthma Reliever Medications			
Description	Prescriptions	Medication Lists	Route
Short-acting, inhaled beta-2 agonists	Albuterol	Albuterol Medications List	Inhalation
Short-acting, inhaled beta-2 agonists	Levalbuterol	Levalbuterol Medications List	Inhalation

# **O** (CWP) Appropriate Testing for Pharyngitis

This measure demonstrates the percentage of episodes for members 3 years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic, and received a group A streptococcus (strep) test for the episode.

#### CPT\*

87070, 87071, 87081, 87430, 87650-87652, 87880

### (FUH) Follow-Up After Hospitalization for Mental Illness

Measure evaluates percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider.

#### Two rates are reported:



Discharges for which the member received **follow-up within** 30 days after discharge



Discharges for which the member received follow-up within 7 days after discharge

Description	Codes*
Visit Setting Unspecified Value Set with Outpatient POS with Mental Health Provider	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251- 99255 <b>POS:</b> 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72
BH Outpatient Visit with Mental Health Provider	<b>CPT:</b> 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99492-99494, 99510, 99483 <b>HCPCS:</b> G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015

## (FUH) Follow-Up After Hospitalization

for Mental Illness (continued)

Description	Codes*
Visit Setting Unspecified Value Set with Partial Hospitalization POS with Mental Health Provider	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251- 99255 <b>POS:</b> 52
Partial Hospitalization/Intensive Outpatient	<b>HCPCS:</b> G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485
Visit Setting Unspecified Value Set with Community Mental Health Center POS	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251- 99255 <b>POS:</b> 53
Electroconvulsive Therapy with Ambulatory Surgical Center POS/ Community Mental Health Center POS/ Outpatient POS/Partial Hospitalization POS	<b>CPT:</b> 90870 <b>Ambulatory POS:</b> 24 <b>Comm. POS:</b> 53 <b>Partial Hosp. POS:</b> 52 <b>Outpatient POS:</b> 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72
Telehealth Visit	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251- 99255 <b>POS:</b> 02, 10
Observation	<b>CPT:</b> 99217-99220
Transitional Care Management	<b>CPT:</b> 99495, 99496
Telephone Visit	<b>CPT:</b> 98966-98968, 99441-99443
Psychiatric Collaborative Care Management	<b>CPT:</b> 99492-99494 <b>HCPCS:</b> G0512

# (IET) Initiation and Engagement of Substance Use Disorder Treatment

Measure evaluates percentage of adolescent and adult members with a new episode of substance use disorder (SUD) episodes that result in treatment initiation and engagement:

- ✓ Initiation of SUD Treatment: percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication treatment within 14 days
- Engagement of SUD Treatment: percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation

Alcohol Use Disorder Treatment Medications		
Description	Prescription	
Aldehyde dehydrogenase inhibitor	Disulfiram (oral)	
Antagonist	Naltrexone (oral and injectable)	
Other	Acamprosafe (oral; delayed-release tablet)	

Opioid Use Disorder Treatment Medications		
Description	Prescription	Medication Lists
Antagonist	Naltrexone (oral)	Naltrexone Oral Medication List
Antagonist	Naltrexone (injectable)	Naltrexone Injection Medication List
Partial agonist	Buprenorphine (sublingual tablet)	Buprenorphine Oral Medication List
Partial agonist	Buprenorphine (injection)	Buprenorphine Injection Medication List

#### (IET) Initiation and Engagement of Substance Use Disorder Treatments (continued)

Opioid Use Disorder Treatment Medications		
Description	Prescription	Medication Lists
Partial agonist	Buprenorphine (implant)	Buprenorphine Implant Medication List
Partial agonist	Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)	Buprenorphine Naloxone Medication List

Description	Codes*
Initiation and Engagement/ Treatment	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99221-99223, 99231, 99232, 99233, 99238, 99239, 99241-99245, 99341-99345, 99347-99350, 99251-99255, 99381-99387, 99391-99397, 99401-99404, 99408, 99409, 99411, 99412, 99483, 99492-99494, 99510 <b>HCPCS:</b> G0155, G0176, G0177, G0396, G0397, G0409, G0443, G0463, G2086, G2087, G0512, G2067-G2078, G2080, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H0050, H2000, H2010, H2011, H2013-H2020, H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012, T1015 <b>POS:</b> 02, 03, 05, 07, 09, 11-20, 22, 33, 49-50, 52-53, 57, 58, 71-72
Telephone Visits	<b>CPT:</b> 98966-98968, 99441-99443
E-visit/Virtual Check-In	<b>CPT:</b> 98969-98972, 99421-99423, 99444, 99457 <b>HCPCS:</b> G0071, G2010, G2012, G2061-G2063

\*Codes subject to change

\*For the follow-up treatments, include an ICD-10 diagnosis for Alcohol or Other Drug Dependence from the Mental, Behavioral and Neurodevelopmental Disorder Section of ICD-10 along with a procedure code for the preventive service, evaluation, and management consultation or counseling service.



www.wellcarenc.com

PRO\_107987E Internal Approved 08182022 ©WellCare 2022

NC2PROGDE13041E\_0000